Department of Orthopaedic Surgery, Mishuku Hospital, 5-33-12 Kamimeguro, Tokyo 153-0051, Japan.
J Bone Miner Metab. 2011 Nov;29(6):645-51. doi: 10.1007/s00774-011-0281-9. Epub 2011 Jun 14.
Computed tomography-based nonlinear finite element method (CT/FEM) can accurately predict vertebral compressive strength ex vivo and this method is clinically available in vivo. This study aimed to assess vertebral fracture risk and alendronate effects on osteoporosis in vivo using CT/FEM. Vertebral strength in 123 postmenopausal women was analyzed and the discriminatory power for vertebral fracture was assessed cross-sectionally. Alendronate effects were also prospectively assessed in 33 patients with postmenopausal osteoporosis who were treated with alendronate at a dose of 5 mg/day for 18 months. CT/FEM had higher discriminatory power for vertebral fracture than areal bone mineral density (BMD) and volumetric BMD and detected alendronate effects at 3 months. Marked bone density increases were noted in juxtacortical areas compared to inner trabecular areas. CT/FEM was useful for assessing vertebral fracture risk and therapeutic effects on osteoporosis.
基于计算机断层扫描的非线性有限元方法（CT/FEM）可以准确预测离体椎体抗压强度，该方法在临床上可用于体内。本研究旨在使用 CT/FEM 评估体内椎体骨折风险和阿仑膦酸钠对骨质疏松症的作用。分析了 123 名绝经后妇女的椎体强度，并进行了横断面分析以评估椎体骨折的鉴别能力。还前瞻性评估了 33 名绝经后骨质疏松症患者使用阿仑膦酸钠（剂量为 5mg/天）治疗 18 个月的效果。CT/FEM 对椎体骨折的鉴别能力高于面积骨密度（BMD）和体积 BMD，并且在 3 个月时可检测到阿仑膦酸钠的作用。与内骨小梁区域相比，皮质下区域的骨密度明显增加。CT/FEM 可用于评估椎体骨折风险和骨质疏松症的治疗效果。
